

HENRY HE

Partner·Shanghai

+86 21 2208 1185

henry.he@fangdalaw.com

PRACTICE AREA

MR. HE SPECIALIZES IN CROSS-BORDER TRANSACTIONS INVOLVING COMPLEX BUSINESS, INTELLECTUAL PROPERTY, OPERATIONAL AND LEGAL ISSUES, INCLUDING STRATEGIC PARTNERSHIPS, PRODUCT AND TECHNOLOGY LICENSING (IN/OUT), ASSET ACQUISITIONS AND DIVESTITURES, PLATFORM DISCOVERY AND OPTION DEALS. ADDITIONALLY, MR. HE COUNSELS LIFE SCIENCES CLIENTS ON DAY-TO-DAY OPERATIONAL MATTERS INVOLVING CLINICAL TRIALS, REGULATORY COMPLIANCE, DRUG SUPPLY AND PROMOTION, RESEARCH AND COMMERCIALIZATION COLLABORATIONS.

Education

- East China University of Political Sciences and Law, LL.B; LL.M
- University of Wisconsin-Madison, LL.M

Professional Qualification

- Admitted to practice in Massachusetts
- Admitted to practice in PRC

Work Language

- Mandarin
- English

REPRESENTATIVE MATTERS AND CASES

Licensing and Corporate Partnering

- Represented **Boomray Pharmaceuticals** to enter into an exclusive global license agreement with **Novartis** for an undisclosed pre-clinical radioligand therapy (RLT) asset, under which BoomRay will be eligible to receive up to US$900 million, including an upfront payment as well as development, regulatory and sales milestone payments, and in addition, royalties may be earned on future global net sales.
- Represented **Zelgen Biopharmaceuticals** in its entering into a Collaboration and Option to License Agreement with **AbbVie** for the global development and commercialization of ZG006, a clinical stage DLL3/DLL3/CD3 trispecific T-cell engager, under which Zelgen will receive an upfront payment of US$100 million, near-term clinical development milestone payment and option-related fees of up to US$60 million; and if AbbVie exercises the option, is eligible to receive milestone payments of up to US$1.075 billion, as well as tiered royalties from high-single-digit to middle-double-digits on net sales of products.
- Represented **Qyuns Therapeutics**, a Hong Kong-listed (2509.HK) biopharmaceutical company focused on discovering, developing and manufacturing innovative pharmaceutical products in numerous transactions including:
    - a licensing and collaboration agreement with **F. Hoffmann-La Roche Ltd** for the global development, manufacture and commercialization of QX031N, a pre-clinical stage long-acting TSLP/IL-33 bispecific antibody, under which Qyuns Therapeutics will receive an upfront payment of US$75 million and is eligible to receive up to US$995 million milestone payments associated with the development, regulatory approval, and commercialization of the product, as well as tiered royalties on potential future product sales.
    - its granting **Caldera Therapeutics** (NewCo, co-founded by prominent investors Lilly Asia

Professional Background

- Mr. He joined Fangda as a partner in 2023. Prior to joining the firm, Mr. He worked as the Board Secretary, Associate Vice President and General Counsel at CStone Pharmaceuticals (2616.HK), a well-renowned public biopharmaceutical company. Before moving in-house, Mr. He had worked at two reputable international law firms (Cooley LLP and Baker & McKenzie) for many years, representing venture capital funds, emerging companies and multinational corporations with exposure to early-stage financing and pre-IPO restructuring, licensing, venture capital, offshore/onshore ESOP matters and corporate M&A.

Ventures, Atlas Venture, and venBio) a global exclusive license to develop, manufacture, and commercialize QX030N (a bispecific antibody program in the field of autoimmune diseases) and acquiring an equity interest in Caldera Therapeutics.

  - a license and collaboration agreement with **Windward Bio** for the worldwide (ex-Greater China) development, manufacture and commercialization of QX027N, a clinical stage long-acting TSLP/IL-13 bispecific antibody, under which Qyuns Therapeutics will receive a total of up to US$700 million payments, including an upfront payment, an equity interest of Windward Bio, development and commercial milestone payments, plus tiered royalties on net sales of QX027N in the licensed territory.

- Represented **Boehringer Ingelheim** in entering a collaboration with **Simcere** for global (ex-China) development and commercialization of SIM0709 (TL1A/IL23p19 bsAb).
- Represented **Health Hope Pharma** (HHP) in its entering into a global licensing and collaboration agreement with **Gilead Sciences** for Encequidar, a first-in-class P-glycoprotein (P-gp) inhibitor in the field of virology.
- Represented **Genrix Bio** (688443.SH) in granting **Cullinan Therapeutics** (CGEM.Nasdaq) an exclusive license to develop, manufacture and commercialize Genrix Bio's Velinotamig, a clinical-stage BCMAxCD3 bispecific T cell engager for autoimmune diseases in the ex-Greater China territory.
  - in an exclusive license agreement with **Cullinan Therapeutics** (CGEM.Nasdaq) for the development, manufacture and commercialization of Genrix Bio's Velinotamig, a clinical-stage BCMAxCD3 bispecific T cell engager for autoimmune diseases in the ex-Greater China territory.
  - in an exclusive license agreement with Fosun Pharma's subsidiary **Yaoyou Pharmaceutical** for the development and commercialization of GR1803 injection (a clinical-stage BCMAxCD3 bispecific T cell engager for autoimmune diseases) in Greater China, with an upfront payment of RMB300 million.
- Represented **Insilico Medicine** in an AI-driven drug discovery collaboration with **SK Biopharmaceuticals** based on its proprietary Pharma.AI platform with total potential deal value exceeding US$2.5 billion.
- Represented **TJ Bio** to enter into a strategic collaboration with **Biogen** under which Biogen will acquire TJ Bio's exclusive rights to Felzartamab (an investigational therapeutic human monoclonal antibody directed against CD38) in the Greater China region. Under the terms of the agreement, TJ Bio will receive a $100 million upfront payment and is eligible to receive up to $750 million in potential commercial and sales milestone payments, plus mid-single-digit to low-double-digit percentage of royalties on potential net sales in the Greater China Region.
- Represented **TJ Bio** to enter into a strategic collaboration with **Sanofi** for developing, manufacturing and commercializing the globally innovative asset CD73 monoclonal antibody (Uliledlimab) in Greater China.
- Represented **Myeloid Cure Bio** in a collaboration agreement with **MSD (China)** for clinical development and commercialization rights of antibody therapeutics in autoimmune diseases.
- Represented **LaNova Medicines** in granting **MSD** an exclusive global to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody, including handling upstream licensing arrangements, under which LaNova will receive an upfront payment of US$588 million and is eligible to receive up to US$2.7 billion in milestone payments associated with the progress of LM-299 across multiple indications.
- Represented **Hansoh Pharma** (3692.HK) in granting **Tortugas Neuroscience** (NewCo, co-founded by investors Cure Ventures and The Column Group) an exclusive license to develop, manufacture and commercialize multiple central nervous system (CNS) drug therapies in ex-Greater China region and acquiring an equity interest in Tortugas Neuroscience.
- Represented **Excalipoint Therapeutics** on the establishment of NewCo, its Series A financing (jointly led by prominent investors HongShan Capital, YuanBio Capital, and Apricot Capital), and the worldwide licensing of a portfolio of multi-specific T-cell engager assets from **Lepu Biopharma** (2157.HK), a leading Chinese pharmaceutical company.
- Represented **Kanghua** (300841.SZ) in granting **HilleVax** (HLVX.Nasdaq) the exclusive rights to develop,

manufacture and commercialize Kanghua's hexavalent virus-like particle (VLP) vaccine candidate for norovirus in the ex-Greater China territory.

- Represented **OTR Therapeutics** in entering multi-program strategic collaboration and license agreement with **Zealand Pharma** (ZEAL.US) to develop novel therapeutics for metabolic diseases, with potential aggregate consideration up to US$2.5 billion.
- Represented **Huaota** in a collaboration and licensing agreement with **Almirall S.A**. to jointly initiate a research and development program advancing an mAb candidate for multiple indications, including medical dermatology.
- Represented **MingMed Biotech** in its out-licensing partnership with **Elanco Animal Health** with respect to its JAK small molecule inhibitor for companion animals in Greater China.
- Represented **CStone Pharmaceuticals**, a Hong Kong-listed (2616.HK) biopharmaceutical company focused on developing and commercializing innovative pharmaceutical products in numerous transactions including:
    - an Asset Purchase Agreement and a Transition Plan Agreement with **Les Laboratoires Servier** under which Servier acquired the TIBSOVO® (Ivosidenib, IDH1 inhibitor) business and any goodwill thereof, including the transferred assets, in Greater China and Singapore.
    - in strategic out-licensing partnerships for commercialization of Sugemalimab (anti-PD-L1 mAb) with **Istituto Gentili** across Western Europe and the UK, with **Ewopharma** in Switzerland and Central & Eastern European countries, with **SteinCares** in in Latin America, and with **Pharmalink** in the Middle East and North Africa countries, respectively.
    - in a collaboration with **3SBio Inc.** for the exclusive commercialization right to anti-PD-1 monoclonal antibody (nofazinlimab) in mainland China
    - in granting an exclusive commercial promotion right to **Allist** (688578.SH), with respect to its approved RET inhibitor Gavreto® (pralsetinib) in mainland China.
    - in a collaboration with **Hengrui Pharmaceuticals** (600276.SH) for the development and commercialization rights to CTLA-4 mAb (CS1002) in Greater China.
    - in China MAH transfer for GAVRETO® (pralsetinib) partnering with **Roche** and **Blueprint Medicines** on drug supply, manufacturing technology transfer, global clinical development and regulatory matters.
- Represented **Jikang Therapeutics** in granting **BioAge Labs** (BIOA.Nasdaq) an exclusive option to through joint research collaboration in-license Jikang's novel apelin receptor (APJ) agonist nanobody program and if exercised, to globally develop, manufacture and commercialize Jikang's novel APJ agonist nanobody.
- Represented **Zelgen Biopharmaceuticals** in its out-licensing collaboration with **Merck** to grant an exclusive commercialization rights for Zelgen's self-developed rhTSH injection in Chinese mainland.
- Represented **UCB** on its strategic collaboration with **BioRay** with respect to the exclusive commercialization of IL-17A and IL-17F inhibitor Bimzelx® (bimekizumab) in China.
- Represented **Frazier Life Sciences** in entering an exclusive license agreement with **Haisco** for a global (ex-China) license for a PDE3/4 inhibitor HSK39004.
- Represented **Adlai Nortye Ltd.** (NASDAQ: ANL) in a license agreement with **ASK Pharma** for the exclusive development, manufacture and commercialization of its proprietary pan-RAS (ON) inhibitor AN9025 in Greater China.
- Represented **Bao Pharmaceutical** and its wholly-owned subsidiary Centergene Pharmaceuticals to enter into a Licensing Agreement with **Organon** for exploiting the innovative investigational asset in assisted reproductive technology (ART), SJ02, a long-acting FSH in BLA Process in China Mainland.
- Represented **CSPC's** wholly-owned subsidiary Shanghai JMT-BIO to enter into an exclusive license agreement with **Jiangsu Alphamab** for developing and commercializing JSKN003 (a biparatopic HER2-targeting antibody-drug conjugate/ADC) in Mainland China, with upfront payment plus near-term development milestones amounting to approx. US$100 million.
- Represented **TargetRx** in an exclusive commercialization transaction with **Simcere Zaiming** with respect to its clinical-stage anti-tumor candidate drug, ALK/ROS1 dual receptor tyrosine kinase inhibitor (TGRX-326) in

mainland China, with an upfront payment exceeding US$20 million.

- Represented **Hengrui Pharmaceuticals** (600276.SH) in its out-licensing partnership with **Aiolos Bio** for the worldwide (ex-Greater China) exploitation of Hengrui's innovative anti-TSLP monoclonal antibody (SHR-1905).
- Represented **Anheart Therapeutics** in granting an exclusive commercialization right with respect to Anheart's lead drug candidate Taletrectinib to Innovent for PRC market and to **Nippon Kayaku**, a Japanese listed company, for Japan market, respectively.
- Represented **Sanegene Bio** on its strategic collaboration with **Huadong Medicine** (0963.SZ) with respect to the siRNA drug development for chronic metabolic diseases.

Regulatory Advisory and General Corporate

- Representing various multinational and domestic life sciences clients including AstraZeneca, Biogen, Boehringer Ingelheim, Brii Biosciences, CStone Pharmaceuticals, CSPC, Everest Medicines, Frazier Life Sciences, Hasten Pharmaceuticals, Hansoh Pharmaceutical, Hengrui Pharmaceuticals, IASO, Insilico Medicine, Laekna Therapeutics, LaNova Medicines, Legend Biotech, Link Cell Therapies, MSD, Novartis AG, Roche Pharmaceuticals, Sanegene Bio, Swift Bridge Bio, InnoRNA, UCB, Vera Therapeutics, WuXi AppTec, Yiling Pharma and Zai Lab, on regulatory advisory and compliance matters arising from day-to-day operations, e.g., research and development projects, clinical trials (including investigator-initiated trials), HGR (human genetic resources) matters, marketing authorization, drug product supply, distribution, advertising and promotion.

Merger & Acquisitions, Venture Capital and Emerging Companies

- Represented **Sino Biopharma** (1177.HK) in its full acquisition of **Hygieia** (a domestic innovative drug company in the small interfering RNA (siRNA) field).
- Represented **AnHeart Therapeutics** in **Nuvation Bio** (NUVB, NYSE)'s acquisition of AnHeart Therapeutics in an all-stock transaction.
- Represented **CStone Pharmaceuticals** in Series B financing, pre-IPO restructuring, licensing, early-stage collaboration and offshore/onshore ESOP-related matters.
- Represented **BioCombo Therapeutics** (a clinical-stage biotech focusing on the development of next-generation antibody-drug conjugates) in its series Pre-A financing led by **Huajin Capital**.
- Represented **Synvida Bio** in its series A financing, with an aggregate fundraising amount of approx. RMB200 million, led by Longpan Investment and Shanghai Healthcare Capital (SHC).
- Represented **Excalipoint Therapeutics** on the establishment of NewCo and its Series A financing (jointly led by prominent investors HongShan Capital, YuanBio Capital, and Apricot Capital).
- Represented **ABM Therapeutics** in its Series A financing and general corporate matters.
- Represented **Qiming Ventures** and **BioTrack Capital** as the lead investors in its equity investment in the Series C financing of Bioheng Therapeutics (a clinical-stage biotech focusing on CAR-T therapies).
- Represented **Qiming Ventures** in its investment as lead investor in Series A financing of **NeuHyll Therapeutics Inc**.
- Represented **BioTrack Capital** in its investment as lead investor in Series Angel and Series Pre-A financings of **SciBrunch Therapeutics**.
- Represented **Shanghai Healthcare Capital** in its investment as lead investor in Series B+ financing of Hexaell Biotech (a clinical-stage biotech focusing on developing novel cell therapies and regenerative medicines for severe liver diseases) with an aggregate fundraising exceeding RMB200 million.
- Represented **Sanofi/Cathay Capital** in its investment as lead investor in financing of **Latticon Antibody Therapeutics**.
- Represented **Eight Roads Ventures** as the lead investor in its equity investment in the Series A financing of New Trials Medical Technology with the aggregate fundraising size over RMB100million.
- Represented **Kyowa Kirin** in its business restructuring of the APAC region through a serial transactions of

transferring all rights and interests of Kyowa Kirin China to Hong Kong WinHealth Pharma Group ("WinHealth") and granting a license to WinHealth to commercialize and manufacture five original branded commercial-stage drugs in China and to commercialize two global products in China.

- Represented various venture capital funds including Eight Roads Ventures, BioTrack Capital, Shanghai Healthcare Capital, Qiming Ventures, Sanofi/Cathay Capital, Yunfeng Capital, OrbiMed, GGV, Matrix China Partners, Decheng Capital in investments/exit transactions across life science, healthcare, e-commerce, financial services, telecommunication and education sectors.
- Represented various emerging growth companies including AlphaMab Oncology, Curative Medical, Genebox, ABM Therapeutic, Quantifeed, Cashshield, Carousell, Gshopper, Yamibuy, Hycor on equity financings (covering series seed through pre-IPO round), restructuring and asset acquisitions.

Publications/Articles

- Co-author, "Encountering and Anchoring Opportunities in an Era of Uncertainty: Exploring the Trends and Core Risks of Mergers and Acquisitions of Chinese Biotech Companies", Legal 500 (September 2024)(1)
- Co-author, "China life sciences: Transaction insights and notable industry trends", Legal 500 (February 2024)(2)
- Co-author, "Life Sciences Yearbook 2024: China life sciences Q&A ", Legal 500 (February 2024)(3)